康臣藥業(01681.HK)2021年純利升18.3%至5.90億元 銷售收入首破20億大關
格隆匯3月23日丨康臣藥業(01681.HK)公佈2021年度業績，期內集團實現銷售收入20.45億元人民幣(單位下同)，同比增長16.6%，首次突破20億大關；公司權益股東應占溢利5.90億元，同比增長18.3%；每股基本盈利0.74元，宣派末期股息每股0.2港元。
從業務分部來看，康臣藥業分部銷售收入約17.33億元，同比增長約15.6%。其中：腎科藥物的銷售收入於2021年約為13.65億元，較去年同比增長約17.1%。本集團龍頭產品尿毒清顆粒繼續保持穩健增長，實現銷售收入13.13億元，同比增長16.7%。根據米內網資料，在降肌酐類中成藥市場(包含尿毒清、腎康注射液、腎衰寧、海昆腎喜等)，尿毒清顆粒2021年的市場份額超過33%，名列第一名，銷售額和市場份額均達歷史新高。於2021年正式公佈的《中成藥治療優勢病種(CKD)臨牀應用指南》中，尿毒清顆粒更以唯一“強推薦”的身份進入指南，進一步強化了公司臨牀推廣的學術基礎。而益腎化濕顆粒也成績喜人，實現銷售收入0.52億元，同比增長33.8%。
玉林製藥分部，銷售收入約為3.12億元，同比增長超22.8%，利潤0.17億元(收購玉林製藥分部產生的公允值調整前)，實現了調整整頓後的首次扭虧為盈。玉林製藥OTC行銷團隊堅持“品牌發聲、管道賦能、終端動銷”的基本策略，深化“精終端、做純銷、煉隊伍、全員下沉”的管理標準，2021下半年起推出連鎖爆破、包銷、路演和產品代言等一系列動作，啟動產品、隊伍、客户，在品牌建設、終端動銷和管道治理方面初見成效，管道秩序和客户滿意度得到顯著提升。
新零售與外貿板塊持續發力，多管道控銷開花結果。集團各新零售自營平台也有突破性進展，實現了多模式齊頭並進，藥品+大健康產品雙線共軌發展。外貿方面，正骨水、羅漢果菊花顆粒完成印尼註冊，截至2021年12月底，集團產品已在28個國家銷售，康臣、玉藥系列產品陸續走向國際。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
